BKBenjamin D. Kuhns

Benjamin D. Kuhns

*This is an algorithmically generated author record based on publicly available information.

Benjamin D. Kuhns has a total of 141 co-authors. Here are the top co-authors by number of shared publications:

  • Shane J. Nho

    Department of Orthopedic Surgery, Division of Sports Medicine, Section of Young Adult Hip Surgery, Rush Medical College of Rush University, Rush University Medical Center, Chicago, IL

    13 shared publications
  • Alexander E. Weber

    Department of Orthopedic Surgery, Division of Sports Medicine, Section of Young Adult Hip Surgery, Rush Medical College of Rush University, Rush University Medical Center, Chicago, IL

    8 shared publications
  • Richard C. Mather

    Division of Sports Medicine, Duke University Medical Center, Durham, NC

    7 shared publications
  • Benjamin Gilbert Domb

    American Hip Institute Research Foundation, Chicago, IL 60018; American Hip Institute, Chicago, IL 60018

    6 shared publications
  • Michael J. Salata

    University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA

    6 shared publications
  • Shane J. Nho

    Section of Young Adult Hip Surgery, Division of Sports Medicine, Department of Orthopedic Surgery Rush University Medical Center Chicago Illinois U.S.A.

    6 shared publications

Latest Publications

  • Short-term outcomes of robotic-assisted direct anterior THA in patients with generalised ligamentous laxity: a propensity-matched study

    by Roger Quesada-Jimenez, Absolon Reyes-Cordova, Dharma H. Patel, Benjamin D. Kuhns, Ady H. Kahana-Rojkind, Benjamin G. Domb

    Background: Generalised ligamentous laxity (GLL) has been linked to instability and implant failure in primary total hip arthroplasty (THA). This study assessed outcomes of GLL patients undergoing robotic-assisted direct anterior approach (DAA) THA. Methods: Retrospectively analysed prospectively collected data from patients who had robotic-assisted primary DAA THA between August 2013 and October 2022, with a minimum 2-year follow-up. Eligible patients completed at least one patient-reported outcome measure (PROMs): modified Harris Hip Score (mHHS), Hip disability and Osteoarthritis Outcome Score for Joint Replacement (HOOS-JR), Forgotten Joint Score (FJS), visual analogue scale (VAS), and satisfaction. Patients with GLL (Beighton ⩾4) were matched 1:2 to controls (Beighton ⩽3) by age, sex, BMI, and follow-up. Outcomes included PROMs changes, achievement of MCID/PASS, complications, and revisions. Results: Of 126 patients, 42 had GLL and 84 were controls. Both groups showed significant improvements in PROMs, high satisfaction, and similar achievement of MCID and PASS. Revision rates were comparable ( p > 0.05): 1 GLL patient (2.4%) for infection and 1 control (1.2%) for aseptic loosening. No dislocations occurred. Conclusions: GLL patients undergoing robotic-assisted DAA THA achieved favorable outcomes and survivorship comparable to controls, with no dislocations at minimum 2-year follow-up. Larger multicentre studies are needed to confirm whether this approach truly mitigates the higher dislocation and revision risk in the GLL populations.

  • Athletes Undergoing Staged Bilateral Hip Arthroscopy Show Favorable Midterm Outcomes and Return to Sport: A Propensity‐Matched Study

    by Ady H. Kahana‐Rojkind, Meredith F. Cohen, Matthew J. Strok, Elizabeth G. Walsh, Roger Quesada‐Jimenez, Benjamin D. Kuhns, Benjamin G. Domb

    Purpose: To evaluate midterm patient‐reported outcomes (PROs) and rates of return to sports of bilateral primary hip arthroscopy in high‐level athletic populations with minimum 5‐year follow‐up and to compare outcomes with a propensity‐matched control group of high‐level athletic populations undergoing unilateral primary hip arthroscopy. Methods: Data were analyzed for high‐level athletic populations (high school, college, or professional) who underwent bilateral hip arthroscopy between July 2009 and January 2019. Patients were included if they had at least one of these PROs at minimum 5‐year follow‐up: modified Harris Hip Score (mHHS), Non‐Arthritic Hip Score, International Hip Outcome Tool‐12, Hip Outcome Score‐Sports Specific Subscale, and Visual Analog Scale for pain. Patients were matched 1:1 to unilateral athletes. Rates of achieving the minimal clinically important difference, patient acceptable symptomatic state, and substantial clinical benefit were compared. Results: Forty‐six bilateral athletes were matched to 46 unilateral athletes. The mean follow‐up of the bilateral group (second side) is 90.1 ± 28.8 (60.0‐130.2) months and 91.4 ± 30.9 (12.3‐136.7) for the unilateral group. All groups showed significant PRO improvement. 84.4% of the bilateral first side achieved mHHS minimal clinically important difference, 78.3% of the second side, and 83.3% of the unilateral group ( P = .716). 73.3% of the bilateral first side achieved mHHS patient acceptable symptomatic state, 78.3% of the second side, and 85.7% of the unilateral group ( P = .364). 57.8% of the bilateral first side achieved mHHS substantial clinical benefit, 60.9% of the bilateral second side, and 76.2% of the unilateral group ( P = .160). Bilateral and unilateral athletes returned to sport at a high rate (88.6% and 85.0%). 80.0% of unilateral and 68.8% of bilateral athletes were playing their sport at minimum 5‐year follow‐up ( P = .31). Seven (15.2%) unilateral athletes underwent ipsilateral secondary arthroscopy. Seven bilateral first side patients (15.2%) and 1 bilateral second side patient (2.2%) underwent ipsilateral secondary arthroscopy. Conclusions: Athletes undergoing staged bilateral hip arthroscopy showed favorable return to sports rates, continuation of sports and PROs at minimum 5‐year follow‐up. These results were comparable with the matched benchmark control group who underwent unilateral hip arthroscopy. Level of Evidence: Level III, retrospective comparative case series.


  • Iliopsoas Tunnel Deepening and Fractional Lengthening Relieve Painful Internal Snapping During Concomitant Primary Hip Arthroscopy for Treatment of Femoroacetabular Impingement: A Propensity Matched Comparison

    by Andrew R. Schab, Benjamin D. Kuhns, Elizabeth G. Walsh, Roger Quesada‐Jimenez, Ady H. Kahana‐Rojkind, Meredith F. Cohen, Benjamin G. Domb

    Purpose: To report minimum 2‐year outcomes of iliopsoas tunnel deepening (ITD) during hip arthroscopy and compare their results to propensity‐matched hip arthroscopies performed with iliopsoas fractional lengthening (IFL) in patients with combined femoroacetabular impingement syndrome and iliopsoas impingement with painful internal snapping. Methods: Data were collected between December 2017 and January 2022 and retrospectively reviewed for all patients who underwent primary hip arthroscopy to treat femoroacetabular impingement syndrome, labral tears, and iliopsoas impingement. Hips included had 2‐year minimum postoperative patient reported outcomes (PRO). Subjects receiving ITD were propensity matched to IFLs in a 1:1 ratio based on age, sex, body mass index, Acetabular Outerbridge Grade, labral treatment, and capsular treatment. Patient characteristics, procedures performed, and PROs were compared. Rates of meeting minimum clinically important difference and patient acceptable symptomatic state, revision arthroscopy, and conversion to arthroplasty were compared. Results: A total of 33 ITD hips (30 patients) and 33 IFL hips (33 patients) were included in each group. Patients in the IFL cohort had longer follow‐up than ITD cohort (56.3 ± 23.9 vs 27.9 ± 9.6 months respectively, P < .01). Both groups showed significant improvement in all PROs with comparable postoperative improvement ( P > .05). Similar resolution of painful internal snapping was seen, with 26 (78.79%) ITD and 27 (81.82%) IFL hips seeing resolution ( P = .76). For ITD and IFL groups, rates of achieving minimum clinically important difference and patient acceptable symptomatic state were similar rates ( P > .05). ITDs and IFLs underwent revision arthroscopy at comparable rates (9.1% vs 9.1%; P > .99). No conversions to arthroplasty were reported. Conclusions: ITD yielded improvements when treating iliopsoas impingement during hip arthroscopy. ITDs had comparable improvements in PROs, resolution in painful internal snapping, and underwent revision arthroscopy at similar rates when compared to IFLs. Level of Evidence: Level III, retrospective comparative study.


  • Improved Outcomes With Platelet‐Rich Plasma for Treating Extra‐articular Hip Pathology Especially Greater Trochanteric Pain Syndrome and Hamstring Injury: A Systematic Review of Randomized Controlled Trials

    by Benjamin D. Kuhns, Nils Becker, Absolon Reyes‐Cordova, Matthew J. Strok, Roger Quesada‐Jimenez, Ady H. Kahana‐Rojkind, Benjamin G. Domb

    Purpose: To perform a systematic review evaluating indications, preparation methods, and outcomes of randomized controlled trials (RCTs) involving platelet‐rich plasma (PRP) injections for extra‐articular hip pathology. Methods: A literature review was performed using the PubMed‐MEDLINE, Embase, and Cochrane databases. Only RCTs evaluating extra‐articular PRP hip injections were included. Study design, patient and disease characteristics, PRP processing methodology using the Platelet‐Activation‐White blood cell (PAW) classification, and patient‐reported outcomes were analyzed. Study quality was assessed by the revised Cochrane risk‐of‐bias tool for randomized trials (RoB2). Meta‐analyses were performed for studies evaluating the same pathology with comparable outcome metrics. Results: Eleven RCTs (581 hips) were included with a focus on hamstring (five studies, 4 acute muscular injury; 208 patients, 1 chronic proximal tendinopathy; 17 patients), greater trochanteric pain syndrome or abductor tendinopathy (five studies; 263 patients), and piriformis (one study; 60 patients) pathology. PRP yielded superior outcomes compared to control groups for at least one time point in three RCTs (60%) on gluteal tendinopathy and two RCTs (50%) evaluating return to sport rate following acute hamstring injury. Meta‐analyses found high heterogeneity (I 2 = .92) in greater trochanteric pain syndrome (GTPS) studies with a significant treatment effect for the modified Harris Hip Score favoring PRP ( P = .005) compared to control groups ( P = .08). There was lower heterogeneity for hamstring studies (I 2 = .65) and a significant treatment effect favoring PRP with an 8‐day shorter return to sport ( P = .005). Conclusions: All RCTs found improvements in pain and function following PRP injection with clinically relevant outcome thresholds and meta‐analyses favoring PRP when treating GTPS and hamstring pathology. While there is substantial heterogeneity in study design, PRP formulations, control groups, outcome metrics, and follow‐up time, all reviewed RCTs showed comparable or superior outcomes with PRP compared to controls. Level of Evidence: Level I, systematic review of Level I randomized controlled trials.


  • Biochemical and Histologic Evaluation of Pulvinar Synovium Provides Insight Into Osteoarthritis Progression Secondary to Femoroacetabular Impingement

    by Benjamin D. Kuhns, Dane R. G. Lind, Adam Goff, Nicholas A. Felan, Kohei Yamaura, Haruki Nishimura, Joel Matta, Raymond Kim, Chelsea S. Bahney, Johnny Huard, et al.

    Recent studies have used femoroacetabular impingement (FAI) as a model for hip osteoarthritis, however, the cellular mechanisms underlying disease progression remain unclear. Pulvinar abnormalities within the cotyloid fossa are common findings during hip preservation surgery and total hip arthroplasty (THA). The purpose of this study was to compare histologic inflammation and gene expression of pulvinar synovial tissue in patients with FAI and patients with hip osteoarthritis secondary to FAI (FAI‐OA). Patients undergoing hip arthroscopy for FAI and THA for osteoarthritis with FAI morphology (FAI‐OA) were included. Macroscopic evaluation of the pulvinar for the FAI cohort was classified through the ligamentum‐fossa‐fovea complex (LFFC) grading system. RNA was isolated for reverse transcription‐polymerase chain reaction to evaluate the expression of inflammatory genes. Synovial samples were graded according to the histologic synovitis scoring system. Twenty‐nine patients were included in the study (17 FAI and 12 FAI‐OA). FAI patients had a lower pulvinar synovial score (2.3 ± 1.1) compared to FAI‐OA patients undergoing THA (3.6 ± 1.7; p = 0.04). Macroscopic pulvinar inflammation in the FAI cohort according to the LFFC classification was associated with worsening histologic synovitis (r = 0.82; p < 0.001). There were no differences in gene expression between the FAI and FAI‐OA cohorts, while there was increased expression of IL1β, TGF‐β1, and PPARγ in subjects without significant pulvinar synovitis. Increased catabolic gene expression by the pulvinar tissue of patients without histologic synovitis earlier in the disease process may promote the development of worsening synovitis and contribute to articular cartilage degeneration.Statement of Clinical Significance: Understanding the role of the pulvinar tissue within the hip, both macroscopically and biochemically, can help surgeons understand the complexities of the presentation and progression of osteoarthritis.


  • Clinically Relevant Thresholds in Patient-Reported Outcomes: Do Patients’ Expectations Evolve Over Long-term Follow-up?

    by Elizabeth G. Walsh, Tyler R. McCarroll, Benjamin D. Kuhns, Ady H. Kahana-Rojkind, Roger Quesada-Jimenez, Benjamin G. Domb

    Background: Clinically relevant thresholds have been utilized to provide insight into postoperative functional status and patient satisfaction. Purpose: To define and evaluate the minimal clinically important difference (MCID), Patient Acceptable Symptom State (PASS), and substantial clinical benefit (SCB) thresholds over the 2-, 5-, and 10-year timepoints for the modified Harris Hip Score (mHHS), Hip Outcome Score–Sports-Specific Subscale (HOS-SSS), and International Hip Outcome Tool (iHOT12). Study Design: Case series; Level of evidence, 4. Methods: Data were retrospectively reviewed for patients who underwent primary hip arthroscopy from 2008 to 2021. The inclusion criteria comprised complete patient-reported outcome scores with anchor questions at the 2-, 5-, or 10-year timepoints. Groups were propensity score–matched 1 to 1 to 1 for these 3 timepoints to limit confounding variables. The PASS, SCB, and MCID thresholds were defined using the anchor-based method for the mHHS, HOS-SSS, and iHOT12. Results: A total of 414 hips were included in the study. Area under the curve for all defined thresholds indicated acceptable to excellent discrimination. The thresholds for achieving the PASS, defined at the 2-, 5-, and 10-year respectively, were as follows: mHHS: 77.5, 85.5, and 78.5; HOS-SSS: 82.7, 76.4, and 67.7; and iHOT12: 67.4, 76.9, and 62.9. The percentage of patients achieving the PASS increased from 2 to 10 years, with the highest percentage at 10 years. The threshold for achieving the SCB was defined as follows: mHHS: 95, 99, and 88; HOS-SSS: 97, 80.9, and 90.5; and iHOT12: 89.4, 94.1, and 82.5. The percentage of patients achieving the SCB increased from 2 to 10 years. The mean changes required to achieve the MCID were defined as follows: mHHS: 7, 7.1, and 7.4; HOS-SSS: 10.6, 10.7, and 11.2; and iHOT12: (9.6, 9.7, -). The MCID and the percentage of patients achieving the MCID remained constant over 2 to 10 years. Conclusion: Patients met the MCID, PASS, and SCB thresholds at high rates over 10 years. Based on the PASS and SCB thresholds, patient expectations for function evolved. Lower expectations at long-term follow-ups may result in a higher percentage of patients meeting certain thresholds, as evidenced in the mHHS, HOS-SSS, and iHOT12 in this cohort. Understanding the evolution of patient expectations may help interpret clinically relevant thresholds in future studies.


  • Low Ceiling Effects of the Forgotten Joint Score Compared With Legacy Measures After Joint‐Preserving Procedures: A Systematic Review

    by Benjamin D. Kuhns, W. Taylor Harris, Benjamin G. Domb

    Purpose: To determine, in patients undergoing joint preservation procedures, whether the Forgotten Joint Score (FJS) compares favorably with legacy measures. Methods: Medical databases (including PubMed/MEDLINE and Embase databases) were queried for publications with the terms “Forgotten Joint Score” and “hip,” “knee,” “arthroscopy,” or “ACL.” Fourteen studies met the inclusion criteria. Methodologic quality was assessed through the Consensus‐based Standards for the Selection of Health Measurement Instruments (COSMIN) checklist, and psychometric data were evaluated for ceiling or floor effects, convergent validity, internal consistency, reliability, responsiveness, measurement invariance, and measurement error by 2 fellowship‐trained orthopaedic surgeons (B.D.K. and W.T.H.). Results: Data were collected from 14 studies using the FJS after joint‐preserving procedures in 911 patients (959 joints). Four studies reported strong internal consistency with an average Cronbach α of 0.92. Two studies reported responsiveness with an effect size ranging from 0.6 to 1.16. One study reported reproducibility with an interclass correlation coefficient of 0.9 (95% confidence interval, 0.8‐0.9). One study reported measurement error with an minimum detectable change (MDC) individual of 32% and MDC group of 4.5%. Studies reported moderate to very strong convergent validity across legacy measures for hip and knee preservation surgery. Ceiling effects were favorable compared with many legacy scores for hip and knee preservation. Three studies reported the minimal clinically important difference whereas 1 study reported the patient acceptable symptomatic state for the FJS. Conclusions: The FJS is a methodologically sound outcome measure used to evaluate patient outcomes after hip and knee preservation surgery with overall low ceiling effects compared with legacy measures. Level of Evidence: Level IV, systematic review of Level III and IV studies.


  • Whole‐genome RNA sequencing identifies distinct transcriptomic profiles in impingement cartilage between patients with femoroacetabular impingement and hip osteoarthritis

    by Benjamin D. Kuhns, John M. Reuter, Victoria L. Hansen, Gillian L. Soles, Jennifer H. Jonason, Cheryl L. Ackert‐Bicknell, Chia‐Lung Wu, Brian D. Giordano

    Femoroacetabular impingement (FAI) has a strong clinical association with the development of hip osteoarthritis (OA); however, the pathobiological mechanisms underlying the transition from focal impingement to global joint degeneration remain poorly understood. The purpose of this study is to use whole‐genome RNA sequencing to identify and subsequently validate differentially expressed genes (DEGs) in femoral head articular cartilage samples from patients with FAI and hip OA secondary to FAI. Thirty‐seven patients were included in the study with whole‐genome RNA sequencing performed on 10 gender‐matched patients in the FAI and OA cohorts and the remaining specimens were used for validation analyses. We identified a total of 3531 DEGs between the FAI and OA cohorts with multiple targets for genes implicated in canonical OA pathways. Quantitative reverse transcription‐polymerase chain reaction validation confirmed increased expression of FGF18 and WNT16 in the FAI samples, while there was increased expression of MMP13 and ADAMTS4 in the OA samples. Expression levels of FGF18 and WNT16 were also higher in FAI samples with mild cartilage damage compared to FAI samples with severe cartilage damage or OA cartilage. Our study further expands the knowledge regarding distinct genetic reprogramming in the cartilage between FAI and hip OA patients. We independently validated the results of the sequencing analysis and found increased expression of anabolic markers in patients with FAI and minimal histologic cartilage damage, suggesting that anabolic signaling may be increased in early FAI with a transition to catabolic and inflammatory gene expression as FAI progresses towards more severe hip OA. Clinical significance:Cam‐type FAI has a strong clinical association with hip OA; however, the cellular pathophysiology of disease progression remains poorly understood. Several previous studies have demonstrated increased expression of inflammatory markers in FAI cartilage samples, suggesting the involvement of these inflammatory pathways in the disease progression. Our study further expands the knowledge regarding distinct genetic reprogramming in the cartilage between FAI and hip OA patients. In addition to differences in inflammatory gene expression, we also identified differential expression in multiple pathways involved in hip OA progression.


  • Open Access

    Whole-Genome RNA Sequencing of Femoral Head Impingement Cartilage Identifies FGF18 As A Biomarker in Hip Osteoarthritis Progression

    by Benjamin D. Kuhns, John M. Reuter, Victoria L. Hansen, Gillian Soles, Jennifer H. Jonason, Cheryl Ackert-Bicknell, Chia-Lung Wu, Brian D. Giordano

    Introduction: The natural history of Femoroacetabular Impingement (FAI) has been clinically associated with the development of hip osteoarthritis (OA); however, the pathobiological mechanisms underlying the transition from focal impingement to global joint degeneration remain unclear. The goal of the study was to investigate differences in transcriptomic profiles of the cartilage from FAI and hip OA patients using whole-genome RNA sequencing. Methods: Thirty-seven patients were included in the study with 20 diagnosed with FAI undergoing arthroscopic treatment and 15 diagnosed with hip OA undergoing total hip arthroplasty (THA). Cartilage samples were obtained intraoperatively over the femoral head-neck junction for both FAI and OA cohorts. Whole-genome RNA sequencing was performed on 10 gender-matched patients in the FAI and OA cohorts with the remaining samples used for histopathologic analysis using the Osteoarthritis Research Society International (OARSI) grading system and qRT-PCR validation. Target validation was further confirmed with immunohistochemical staining for FGF18 on FAI and OA cartilage samples. Results: We identified a total of 3,531 Differentially Expressed Genes (DEGs) between the FAI and OA cohorts with multiple targets for genes implicated in canonical OA pathways. qRT-PCR validation confirmed increased expression of FGF18 and WNT16 in the FAI samples, while there was increased expression of MMP13 and ADAMTS4 in the OA samples. Expression levels of FGF18 and WNT16 were also higher in FAI samples with mild cartilage damage (OARSI grades 1-2) compared to FAI samples with severe cartilage damage or OA cartilage (OARSI grade 4-6). Immunohistochemical evaluation identified increased FGF18 staining in OARSI grade 1-2 FAI samples compared to OARSI grade 5-6 FAI and OA samples. Conclusions: RNA sequencing of cartilage of FAI and hip OA patients identified a negative association of FGF18 expression levels with cartilage damage severity, suggesting that FGF18 may be used as a marker for hip OA progression. Future evaluation of FGF18 signaling as well as other markers in early OA may yield further insight into disease prevention and treatment.

  • Clinically Depressed Patients Having Anterior Cruciate Ligament Reconstruction Show Improved but Inferior Rate of Achieving Minimum Clinically Important Difference for Patient‐Reported Outcomes Measurement Information System Compared With Situationally Depressed or Nondepressed Patients

    by Joseph C. Schaffer, Benjamin Kuhns, John Reuter, Connor Sholtis, Steven Karnyski, John P. Goldblatt, Robert D. Bronstein, Michael D. Maloney, Judith Baumhauer, Sandeep Mannava

    Purpose: To determine whether the preoperative diagnosis of depression predicted worse postoperative outcomes, including physical therapy (PT) compliance, return‐to‐sport, and patient‐reported outcomes using the Patient‐Reported Outcomes Measurement Information System (PROMIS) after anterior cruciate ligament (ACL) reconstruction. Methods: A multisurgeon series of consecutive patients who had undergone ACL reconstruction with minimum 2‐year follow‐up were included. Chart review was conducted to determine depression diagnosis status, demographic data, rehabilitation PT compliance, return to sports, and patient‐reported outcome data using PROMIS. Patients who met the PROMIS threshold for mild depression but did not carry a clinical diagnosis of depression were classified as “situationally depressed.” Results: Ninety‐five of 115 consecutive patients (81%) met inclusion criteria with an average follow‐up of 34 ± 1.9 months. Fourteen patients (15%) had a preoperative diagnosis of depression, whereas 21 (22%) were considered situationally depressed. Clinically depressed patients had a greater rate of PT noncompliance (33.2% ± 17.6% vs 21.9% ± 12.6%; P = .02) and a lower postoperative PROMIS Physical Function (50.8 ± 7.7 vs 57.8 ± 11.0; P = .03 compared with patients without depression. Situationally depressed patients had lower preoperative physical function (35.4 vs 42.5; P = .04) with no differences in postoperative outcomes scores compared to the non‐depressed cohort.19/21 (90.5%) of situationally depressed patients had postoperative resolution of their depressive symptoms. Conclusions: Situationally depressed patients without a clinical diagnosis of depression can expect significant improvements in both pain and function, as well as a resolution of their depressed mood based on PROMIS scores as they progress through recovery after ACL reconstruction. Clinically depressed patients also experience significant improvements; however, their rate of achieving the minimum clinically important difference for PROMIS outcomes may be less than their nondepressed or situationally depressed counterparts. Level of Evidence: III, prognostic comparative trial.